✦ LIBER ✦

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

✍ Scribed by Nava Siegelmann-Danieli; Daniel Kurnik; Yossi Lomnicky; Janet Vesterman-Landes; Itzhak Katzir; Martin Bialik; Ronen Loebstein

Publisher: Springer US
Year: 2010
Tongue: English
Weight: 170 KB
Volume: 125
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-010-1008-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Masatsugu Okishiro; Tetsuya Taguchi; Seung Jin Kim; Kenzo Shimazu; Yasuhiro Tama 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 469 KB 👁 1 views

Reply to Genetic polymorphisms of CYP2D6

Reply to Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Shinzaburo Noguchi; Masatsugu Okishiro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 1 views